



Patent
Attorney's Docket No. 033352-010

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Cruz, et al.) Group Art Unit: 1653
Application No.: 09/978,309) Examiner: Unassigned
Filed: October 15, 2001)
For: Compositions and Methods for Treating)
Cellular Response to Injury and Other)
Proliferating Cell Disorders Regulated by)
Hyaladherin and Hyaluronans)

SWL
12-15-03

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56,
Applicants hereby submit the following information in conformance with 37 C.F.R.
§§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited
below is enclosed.

- | | | | |
|-----|-----------|----------|------------------------|
| 1. | RE32,011 | 10/22/85 | Zimmerman et al. |
| 2. | 4,018,884 | 4/19/77 | Cleeland, Jr. et al. |
| 3. | 4,359,535 | 11/16/82 | Pieczenik |
| 4. | 4,376,110 | 3/8/83 | David et al. |
| 5. | 4,411,993 | 10/25/83 | Gillis |
| 6. | 4,486,530 | 12/4/84 | David et al. |
| 7. | 4,528,266 | 7/9/85 | Pieczenik |
| 8. | 4,543,439 | 9/24/85 | Frackelton, Jr. et al. |
| 9. | 4,551,433 | 11/5/85 | DeBoer |
| 10. | 4,603,112 | 7/29/86 | Paoletti et al. |
| 11. | 4,736,866 | 4/12/88 | Leder et al. |

TECH CENTER 1600/2900

FEB 26 2002

RECEIVED

12.	4,744,981	5/17/88	Pavanasasivam
13.	4,745,051	5/17/88	Smith et al.
14.	4,769,330	9/6/88	Paoletti et al.
15.	4,816,567	3/28/89	Snyder et al.
16.	4,851,341	7/25/89	Hopp et al.
17.	4,870,009	9/26/89	Evans et al.
18.	4,873,191	10/10/89	Wagner et al.
19.	4,897,255	1/30/90	Fritzberg et al.
20.	4,902,614	2/20/90	Wakabayashi et al.
21.	4,987,071	1/22/91	Cech et al.
22.	4,988,496	1/29/91	Srinivasan et al.
23.	5,017,487	5/21/91	Stunnenberg et al.
24.	5,087,571	2/11/92	Leder et al.
25.	5,091,309	2/25/92	Schlesinger et al.
26.	5,106,951	4/21/92	Morgan, Jr. et al.
27.	5,110,833	5/5/92	Mosbach
28.	5,166,057	11/24/92	Palese et al.
29.	5,162,215	11/10/92	Bosselman et al.
30.	5,169,784	12/8/92	Summers et al.
31.	5,175,383	12/29/92	Leder et al.
32.	5,175,384	12/29/92	Krimpenfort et al.
33.	5,204,244	4/20/93	Fell et al.
34.	5,217,879	6/8/93	Huang et al.
35.	5,219,740	6/15/93	Miller et al.
36.	5,221,778	6/22/93	Byrne et al.
37.	5,225,539	7/6/93	Winter
38.	5,242,687	9/7/93	Fernandez-Pol
39.	5,243,041	9/7/93	Tykocinski et al.
40.	5,254,678	10/19/93	Haseloff et al.

swl
12-15-03

41.	5,266,317	11/30/93	Tomalski et al.
42.	5,288,514	2/22/94	Ellman
43.	5,288,641	2/22/94	Roizman
44.	5,328,834	7/12/94	Ngo et al.
45.	5,359,051	10/25/94	Cook et al.
46.	5,387,742	2/7/95	Cordell
47.	5,347,075	9/13/94	Sorge
48.	5,395,750	3/7/95	Dillon et al.
49.	5,463,564	10/31/95	Agrafiotis et al.
50.	5,482,856	1/9/96	Fell, Jr. et al.
51.	5,506,337	4/9/96	Summerton et al.
52.	5,545,808	8/13/96	Hew et al.
53.	5,567,607	10/22/96	Zhao et al.
54.	5,580,859	12/3/96	Felgner et al.
55.	5,591,624	1/7/97	Barber et al.
56.	5,633,076	5/27/97	DeBoer et al.
57.	5,693,761	12/2/97	Queen et al.
58.	5,693,762	12/2/97	Queen et al.
59.	5,698,435	12/16/97	Robinson et al.
60.	5,716,613	2/10/98	Guber et al.
61.	5,716,826	2/10/98	Gruber et al.
62.	5,716,832	2/10/98	Barber et al.
63.	5,741,957	4/21/98	Deboer et al.
64.	5,770,380	6/23/98	Hamilton et al.
65.	5,780,009	7/14/98	Karatzas et al.
66.	5,780,225	7/14/98	Karatzas et al.
67.	5,789,245	8/4/98	Dubensky, Jr. et al.
68.	5,814,482	9/29/98	Dubensky, Jr. et al.
69.	5,817,491	10/6/98	Yee et al.

SWL
12-15-03

70.	5,843,723	12/1/98	Dubensky, Jr. et al.
71.	5,851,529	12/22/98	Guber et al.
72.	5,840,479	11/24/98	Little et al.
73.	5,849,288	12/15/98	Reisner
74.	5,872,005	2/16/99	Wang et al.
75.	EP 0360 257	11/13/96	
76.	EP 0415 731	3/6/91	
77.	EP 044 0219	8/7/91	
78.	EP 0612844 (A2)	8/31/94	
79.	WO 89/01973	3/9/89	
80.	WO 90/02809	3/22/90	
81.	WO 90/07862	7/26/90	
82.	WO 90/07936	7/26/90	
83.	WO 91/00285	1/10/91	
84.	WO 92/06693	4/30/94	
85.	WO 92/15677	9/17/92	
86.	WO 92/15679	9/17/92	
87.	WO 93/10218	5/27/93	
88.	WO 93/11230	6/10/93	
89.	WO 93/12227	6/24/93	
90.	WO 93/20242	10/14/93	
91.	WO 93/25234	12/23/93	
92.	WO 93/25698	12/23/93	
93.	WO 94/03622	2/17/94	
94.	WO 95/02566	1/26/95	
95.	WO 95/04277	2/9/95	
96.	WO 95/10607	4/20/95	
97.	WO 95/12387	5/11/95	
98.	WO 95/16209	6/15/95	

sw ✓
12-15-03

99. WO 95/16712 6/22/95
100. WO 95/16918 6/22/95
101. WO 95/24186 9/14/95
102. WO 95/24929 9/21/95
103. WO 95/30642 11/16/95
104. WO 96/00148 1/4/96
105. WO 97/38098 10/16/97
106. WO 99/01164 1/14/99:
107. Bauer, et al., "A genetic enrichment for mutations constructed by oligodeoxynucleotide-directed mutagenesis", *Gene*, 37:73-81, (1985).
108. Bird, et al., "Single-chain antigen-binding proteins", *Science*, 242:423-426, (1988).
109. Brinster, et al., "Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs", *Proc. Natl. Acad. Sci. U.S.A.*, 82:4438-4442, (1985).
110. Chothia, et al., "Domain association in immunoglobulin molecules", *J. Mol. Biol.*, 186:651, (1985).
111. Craik, et al., "Use of Oligonucleotides for site-specific mutagenesis", *BioTechniques*, pp. 12-19, (Jan. 1985).
112. Curiel, et al., "High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes", *Hum. Gene Ther.*, 3:147-154, (1992).
113. Drinkwater, et al., "Chemically induced mutagenesis in a shuttle vector with a low-background mutant frequency", *PNAS*, 83:3402-3406, (1986).
114. Fisher-Hoch, et al., "Protection of rhesus monkeys from fata Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene", *PNAS*, 86:317-321, (1989).
115. Flexner, et al., "Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2", *Vaccine*, 8:17-21, (1990).
116. Flexner, et al., "Vaccinia virus expression vectors", *Ann. N.Y. Acad. Sci.*, 569:86-103, (1989).
117. Forster, et al., "Self-cleavage of plus and minus RNAs of virusoid and a structural model for the active sites", *Cell*, 48:211-220, (1987).

sw 2
12-15-03

118. Hammer, et al., "Production of transgenic rabbits, sheep and pigs by microinjection", *Nature*, 315:680-683, (1985).
119. Haseloff, J., et al., "Simple RNA enzymes with new and highly specific endoribonuclease activities", *Nature*, 334:585-591, (1988).
120. Hirashima, et al., "A new immune system against viral infection using antisense RNA: micRNA-immune system", *Molecular Biology of RNA: New Perspectives*, Academic Press, San Diego, CA, pp. 401-412, (1987).
121. Hopp, et al., "A short polypeptide marker sequence useful for recombinant protein identification and purification", *Bio/Technology*, 6:1204-1210, (1988).
122. Horwitz, et al., "Selection of new biological activities from random nucleotide sequences: evolutionary and practical considerations", *Genome*, 3:112-117, (1989).
123. Huse, et al., "Generation of large combinatorial library of the immunoglobulin repertoire in phage lambda", *Science*, 246:1275-1281, (1989).
124. Inman, J., "Covalent linkage of functional groups, ligands, and proteins to polyacrylamide beads", *Methods In Enzymology*, Vol. 34, *Affinity techniques, Enzyme Purification: Part B*, pp. 31-59, Jakoby and Wilcheck (eds.), Academic Press, New York, (1974).
125. Jones, et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse", *Nature*, 321:522-525, (1986).
126. Kit, *Adv. Exp. Med. Biol.*, 215:219-236 (1989).
127. Kohler, et al., "Continuous cultures of fused cells secreting antibody of predefined specificity", *Nature*, 256:495-497, (1975).
128. Kyte, et al., "A simple method for displaying the hydropathic character of a protein", *J. Mol., Biol.*, 157:105-132, (1982).
129. Liao, et al., "A simple high-efficiency method for random mutagenesis of cloned genes using forced nucleotide misincorporation", *Gene*, 88:107-111, (1990).
130. Look, et al., "The Identification of Cyclooxygenase-1 Inhibitors from 4-Thiazolidinone Combinatorial Libraries," *Bioorg and Med. Chem. Letters*, 6:707-712, (1996).
131. Luytjes, et al., "Amplification, express, and packaging of a foreign gene by influenza virus", *Cell*, 59:1107-1113, (1989).

601
12-15-03

132. Mastronardi, et al., "Demyelination in a transgenic mouse: a model for multiple sclerosis", *J. Neurosci. Res.*, (93), Vol. 36, pp. 315-324.
133. Morrison, et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains", *Proc. Natl. Acad. Sci. U.S.A.*, 81:6851-6855, (1984).
134. McMichael, et al., "Cytotoxic t-cell immunity to influenza", *N. Eng. J. Med.*, 309: 13-17, (1983).
135. Mulligan, et al., "Synthesis of rabbit- β -globin in cultured monkey kidney cells following infection with a SV40 β -globin recombinant genome", *Nature*, 277:108-114, (1979).
136. Novotny et al., "Structural invariants of antigen binding: comparison of immunoglobulin VL-VH and VL-VL domain dimers" *Proc. Natl. Acad. Sci. U.S.A.*, 82:4592-4596, (1985).
137. Palmiter, et al., "Metallothionein-human GH fusion genes stimulate growth of mice", *Science*, 222:809-814, (1983).
138. Palmiter, et al., "Transgenic mice", *Cell*, 41:343-345, (1985).
139. Phillips, et al., "Solid-phase Synthesis of Benzimidazoles," *Tet. Letters*, 37:4887-4890, (1996).
140. Poznansky, "Gene transfer into human lymphocytes by a defective human immunodeficiency virus type-1 vector", *J. Virol.*, 65:532-536, (1991).
141. Presta, L., "Antibody engineering", *Curr. Op. Struct., Biol.*, 2:593-596, (1992).
142. Reichmann, et al., "Reshaping human antibodies for therapy", *Nature*, 332:323-327 (1988).
143. Ruhland, et al., "Solid-supported Combinatorial Synthesis of Structurally Diverse Beta-Lactams", *J. Amer. Chem. Soc.*, 111:253-254, (1996).
144. Sastry, et al., "Cloning of immunological repertoire in *Escherichia coli* for generation of monoclonal catalytic antibodies: construction of a heavy chain variable region-specific cDNA library:", *Proc. Natl. Acad. Sci. U.S.A.*, 86:5728-5732, (1989).
145. Scatchard, G., "The attractions of proteins for small molecules and ions", *Ann. N.Y. Acad. Scien.*, 51:660-672, (1949).

swl
12-15-03

146. Stein, et al., "Antisense oligonucleotides as therapeutic agents-is the bullet really magical?", *Science*, 261:1004-1012, (1993).
147. Uhlenbeck, O., "A small catalytic oligoribonucleotide", *Nature*, 328:596-600, (1988).
148. von Heijne, "Signal sequences: the limits of variation", *J. Mol. Biol.*, 184:99-105, (1985).
149. Walbot, et al., "Plant development and ribozymes for pathogens", *Nature*, 334:196-197, (1988).
150. Walder, et al., "Oligodeoxynucleotide-directed mutagenesis using the yeast transformation system", *Gene*, 42:133-139, (1986).
151. Wang, et al., "The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression", *Clinical Cancer Research*, 4:567-576, (1998).
152. Wilchek, et al., "The Avidin-Biotin Complex in Bioanalytical Applications", *Anal. Biochem.*, 171:1-32, (1988).
153. Wu, et al., "Targeting genes: delivery and persistent expression of a foreign gene driven by mammalian regulatory elements *in vivo*", *J. of Biol. Chem*, 264:16985-16987, (1989).
154. Yap, et al., *Nature*, 273:238-239, (1978).
155. Zaho, et al., "Influence of ⁷Li on disease progression in murine models of diabetes: differences between NOD and obese mice", *Lithium*, 2(4), pp. 227-234, (1991).

swl
12-15-03